Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA.
Aged
Aged, 80 and over
Arrhythmias, Cardiac
/ epidemiology
Biomarkers
/ blood
Blood Glucose
/ metabolism
Coronary Stenosis
/ diagnostic imaging
Female
Hospital Mortality
Humans
Hyperglycemia
/ blood
Italy
/ epidemiology
MINOCA
/ diagnostic imaging
Male
Middle Aged
Patient Admission
Prevalence
Prognosis
Prospective Studies
Registries
Risk Assessment
Risk Factors
Severity of Illness Index
Time Factors
Acute myocardial infarction
Long-term prognosis
MINOCA
MIOCA
Short-term prognosis
Stress-hyperglycemia
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
24 09 2021
24 09 2021
Historique:
received:
10
07
2021
accepted:
10
09
2021
entrez:
25
9
2021
pubmed:
26
9
2021
medline:
8
2
2022
Statut:
epublish
Résumé
The prognostic role of hyperglycemia in patients with myocardial infarction and obstructive coronary arteries (MIOCA) is acknowledged, while data on non-obstructive coronary arteries (MINOCA) are still lacking. Recently, we demonstrated that admission stress-hyperglycemia (aHGL) was associated with a larger infarct size and inflammatory response in MIOCA, while no differences were observed in MINOCA. We aim to investigate the impact of aHGL on short and long-term outcomes in MIOCA and MINOCA patients. Multicenter, population-based, cohort study of the prospective registry, designed to evaluate the prognostic information of patients admitted with acute myocardial infarction to S. Orsola-Malpighi and Maggiore Hospitals of Bologna metropolitan area. Among 2704 patients enrolled from 2016 to 2020, 2431 patients were classified according to the presence of aHGL (defined as admission glucose level ≥ 140 mg/dL) and AMI phenotype (MIOCA/MINOCA): no-aHGL (n = 1321), aHGL (n = 877) in MIOCA and no-aHGL (n = 195), aHGL (n = 38) in MINOCA. Short-term outcomes included in-hospital death and arrhythmias. Long-term outcomes were all-cause and cardiovascular mortality. aHGL was associated with a higher in-hospital arrhythmic burden in MINOCA and MIOCA, with increased in-hospital mortality only in MIOCA. After adjusting for age, gender, hypertension, Killip class and AMI phenotypes, aHGL predicted higher in-hospital mortality in non-diabetic (HR = 4.2; 95% CI 1.9-9.5, p = 0.001) and diabetic patients (HR = 3.5, 95% CI 1.5-8.2, p = 0.003). During long-term follow-up, aHGL was associated with 2-fold increased mortality in MIOCA and a 4-fold increase in MINOCA (p = 0.032 and p = 0.016). Kaplan Meier 3-year survival of non-hyperglycemic patients was greater than in aHGL patients for both groups. No differences in survival were found between hyperglycemic MIOCA and MINOCA patients. After adjusting for age, gender, hypertension, smoking, LVEF, STEMI/NSTEMI and AMI phenotypes (MIOCA/MINOCA), aHGL predicted higher long-term mortality. aHGL was identified as a strong predictor of adverse short- and long-term outcomes in both MIOCA and MINOCA, regardless of diabetes. aHGL should be considered a high-risk prognostic marker in all AMI patients, independently of the underlying coronary anatomy. Trial registration data were part of the ongoing observational study AMIPE: Acute Myocardial Infarction, Prognostic and Therapeutic Evaluation. ClinicalTrials.gov Identifier: NCT03883711.
Sections du résumé
BACKGROUND
The prognostic role of hyperglycemia in patients with myocardial infarction and obstructive coronary arteries (MIOCA) is acknowledged, while data on non-obstructive coronary arteries (MINOCA) are still lacking. Recently, we demonstrated that admission stress-hyperglycemia (aHGL) was associated with a larger infarct size and inflammatory response in MIOCA, while no differences were observed in MINOCA. We aim to investigate the impact of aHGL on short and long-term outcomes in MIOCA and MINOCA patients.
METHODS
Multicenter, population-based, cohort study of the prospective registry, designed to evaluate the prognostic information of patients admitted with acute myocardial infarction to S. Orsola-Malpighi and Maggiore Hospitals of Bologna metropolitan area. Among 2704 patients enrolled from 2016 to 2020, 2431 patients were classified according to the presence of aHGL (defined as admission glucose level ≥ 140 mg/dL) and AMI phenotype (MIOCA/MINOCA): no-aHGL (n = 1321), aHGL (n = 877) in MIOCA and no-aHGL (n = 195), aHGL (n = 38) in MINOCA. Short-term outcomes included in-hospital death and arrhythmias. Long-term outcomes were all-cause and cardiovascular mortality.
RESULTS
aHGL was associated with a higher in-hospital arrhythmic burden in MINOCA and MIOCA, with increased in-hospital mortality only in MIOCA. After adjusting for age, gender, hypertension, Killip class and AMI phenotypes, aHGL predicted higher in-hospital mortality in non-diabetic (HR = 4.2; 95% CI 1.9-9.5, p = 0.001) and diabetic patients (HR = 3.5, 95% CI 1.5-8.2, p = 0.003). During long-term follow-up, aHGL was associated with 2-fold increased mortality in MIOCA and a 4-fold increase in MINOCA (p = 0.032 and p = 0.016). Kaplan Meier 3-year survival of non-hyperglycemic patients was greater than in aHGL patients for both groups. No differences in survival were found between hyperglycemic MIOCA and MINOCA patients. After adjusting for age, gender, hypertension, smoking, LVEF, STEMI/NSTEMI and AMI phenotypes (MIOCA/MINOCA), aHGL predicted higher long-term mortality.
CONCLUSIONS
aHGL was identified as a strong predictor of adverse short- and long-term outcomes in both MIOCA and MINOCA, regardless of diabetes. aHGL should be considered a high-risk prognostic marker in all AMI patients, independently of the underlying coronary anatomy. Trial registration data were part of the ongoing observational study AMIPE: Acute Myocardial Infarction, Prognostic and Therapeutic Evaluation. ClinicalTrials.gov Identifier: NCT03883711.
Identifiants
pubmed: 34560876
doi: 10.1186/s12933-021-01384-6
pii: 10.1186/s12933-021-01384-6
pmc: PMC8464114
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Banques de données
ClinicalTrials.gov
['NCT03883711']
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
192Informations de copyright
© 2021. The Author(s).
Références
Cardiovasc Diabetol. 2018 Nov 29;17(1):152
pubmed: 30497513
J Clin Med. 2020 Jan 06;9(1):
pubmed: 31935874
Am Heart J. 2009 Dec;158(6):989-97
pubmed: 19958866
Circulation. 2018 Nov 13;138(20):e618-e651
pubmed: 30571511
Front Pharmacol. 2020 Jan 31;10:1606
pubmed: 32082147
Heart. 2016 Feb 15;102(4):278-84
pubmed: 26567228
J Am Heart Assoc. 2016 Dec 16;5(12):
pubmed: 27986756
Int J Cardiol. 2017 Jun 1;236:9-15
pubmed: 28126258
Diabetes Care. 2019 Oct;42(10):1946-1955
pubmed: 30796109
Eur Heart J. 2005 Apr;26(7):650-61
pubmed: 15728645
Eur Heart J. 2020 Feb 14;41(7):879-881
pubmed: 31377808
Diabetes Care. 2005 Oct;28(10):2551-3
pubmed: 16186299
Lancet. 2000 Mar 4;355(9206):773-8
pubmed: 10711923
J Cell Physiol. 2020 Feb;235(2):1438-1452
pubmed: 31294459
Eur Heart J. 2019 Oct 14;40(39):3215-3217
pubmed: 31608951
Diabetes Care. 2021 Jan;44(Suppl 1):S73-S84
pubmed: 33298417
Diab Vasc Dis Res. 2020 Jan-Feb;17(1):1479164119883983
pubmed: 31726871
Circulation. 2008 Mar 25;117(12):1610-9
pubmed: 18299505
Cardiovasc Diabetol. 2019 Feb 28;18(1):22
pubmed: 30819191
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Int J Cardiol. 2018 Jun 15;261:18-23
pubmed: 29563017
J Am Heart Assoc. 2019 Jul 16;8(14):e011990
pubmed: 31284804
Cardiovasc Diabetol. 2021 Feb 2;20(1):33
pubmed: 33530978
J Epidemiol Community Health. 2017 Jan;71(1):25-32
pubmed: 27307468
Ther Adv Cardiovasc Dis. 2015 Dec;9(6):412-24
pubmed: 26194489
Circulation. 2019 Apr 30;139(18):e891-e908
pubmed: 30913893
J Am Coll Cardiol. 1995 Jul;26(1):57-65
pubmed: 7797776
Circulation. 2005 Jun 14;111(23):3078-86
pubmed: 15939812
Microcirculation. 2003 Apr;10(2):113-26
pubmed: 12700580
Am Heart J. 2014 Oct;168(4):466-470.e1
pubmed: 25262255
Eur Heart J Cardiovasc Pharmacother. 2015 Oct;1(4):220-8
pubmed: 27532445
J Clin Endocrinol Metab. 2012 Jan;97(1):16-38
pubmed: 22223765
BMC Cardiovasc Disord. 2016 May 23;16:102
pubmed: 27216220
J Am Coll Cardiol. 2013 Jul 23;62(4):263-71
pubmed: 23684677
Eur Heart J. 2017 Jan 14;38(3):143-153
pubmed: 28158518
Eur Heart J. 2018 Sep 14;39(35):3335
pubmed: 29850804
Crit Care Med. 2013 Jun;41(6):e93-4
pubmed: 23685597